190 related articles for article (PubMed ID: 27292817)
21. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder.
Gommoll CP; Greenberg WM; Chen C
J Drug Assess; 2014; 3(1):10-9. PubMed ID: 27536449
[TBL] [Abstract][Full Text] [Related]
22. Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo.
Kornstein SG; Fava M; Jiang Q; Tourian KA
Psychopharmacol Bull; 2009; 42(3):21-35. PubMed ID: 19752839
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies.
Nelson JC; Weiller E; Zhang P; Weiss C; Hobart M
J Affect Disord; 2018 Feb; 227():103-108. PubMed ID: 29055257
[TBL] [Abstract][Full Text] [Related]
24. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
Robinson DS; Gilmor ML; Yang Y; Moonsammy G; Azzaro AJ; Oren DA; Campbell BJ
Psychopharmacol Bull; 2007; 40(3):15-28. PubMed ID: 18007565
[TBL] [Abstract][Full Text] [Related]
25. Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder.
Thase ME; Gommoll C; Chen C; Kramer K; Sambunaris A
Int Clin Psychopharmacol; 2016 Nov; 31(6):332-40. PubMed ID: 27455513
[TBL] [Abstract][Full Text] [Related]
26. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.
Soares CN; Kornstein SG; Thase ME; Jiang Q; Guico-Pabia CJ
J Clin Psychiatry; 2009 Oct; 70(10):1365-71. PubMed ID: 19906341
[TBL] [Abstract][Full Text] [Related]
27. Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial.
Citrome L; Gommoll CP; Tang X; Nunez R; Mathews M
Int Clin Psychopharmacol; 2015 Mar; 30(2):75-81. PubMed ID: 25396353
[TBL] [Abstract][Full Text] [Related]
28. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
[TBL] [Abstract][Full Text] [Related]
29. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.
Trivedi MH; Corey-Lisle PK; Guo Z; Lennox RD; Pikalov A; Kim E
Int Clin Psychopharmacol; 2009 May; 24(3):133-8. PubMed ID: 19318972
[TBL] [Abstract][Full Text] [Related]
30. Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.
Scott LJ
CNS Drugs; 2014 Nov; 28(11):1071-82. PubMed ID: 25270036
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Tran P; Skolnick P; Czobor P; Huang NY; Bradshaw M; McKinney A; Fava M
J Psychiatr Res; 2012 Jan; 46(1):64-71. PubMed ID: 21925682
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of levomilnacipran extended release in treating major depressive disorder.
Ragguett RM; Yim SJ; Ho PT; McIntyre RS
Expert Opin Pharmacother; 2017 Dec; 18(18):2017-2024. PubMed ID: 29195487
[TBL] [Abstract][Full Text] [Related]
34. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
[TBL] [Abstract][Full Text] [Related]
35. Time course of improvement of different symptom clusters in patients with major depression and pain treated with duloxetine or placebo.
Demyttenaere K; Desaiah D; Petit C; Croenlein J; Brecht S
Curr Med Res Opin; 2012 Jan; 28(1):41-8. PubMed ID: 22126422
[TBL] [Abstract][Full Text] [Related]
36. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
Weisler RH; Khan A; Trivedi MH; Yang H; Eudicone JM; Pikalov A; Tran QV; Berman RM; Carlson BX
J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039
[TBL] [Abstract][Full Text] [Related]
37. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies.
Trivedi MH; Bandelow B; Demyttenaere K; Papakostas GI; Szamosi J; Earley W; Eriksson H
Int J Neuropsychopharmacol; 2013 Sep; 16(8):1733-44. PubMed ID: 23673347
[TBL] [Abstract][Full Text] [Related]
39. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
[TBL] [Abstract][Full Text] [Related]
40. The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: Secondary and post hoc analyses.
McIntyre RS; Durgam S; Kozauer SG; Chen R; Huo J; Davis RE; Cutler AJ
Eur Neuropsychopharmacol; 2023 Mar; 68():78-88. PubMed ID: 36640735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
